Primary Biliary Cholangitis (PBC)
PBC is a chronic autoimmune cholestatic liver disease characterized by progressive destruction of intrahepatic bile ducts, leading to cholestasis, fibrosis, cirrhosis, and eventually liver failure. Early treatment improves survival and delays need for transplantation.
Symptoms
- Many asymptomatic at diagnosis (abnormal alkaline phosphatase on labs)
- Fatigue, pruritus (worse at night), dry eyes/mouth (sicca symptoms)
- Right upper quadrant discomfort, xanthelasmas, hyperpigmentation
- Later: jaundice, edema, ascites, osteopenia/osteoporosis
Risk Factors
- Female sex (90%)
- Middle age (40–60)
- Family history, other autoimmune diseases (thyroid, Sjögren’s, scleroderma)
- Smoking, recurrent UTIs
Diagnosis
Requires 2 of 3 criteria:
1. Elevated alkaline phosphatase (≥1.5 times ULN for ≥6 months)
2. Positive anti-mitochondrial antibodies (AMA) or PBC-specific ANA (gp210, sp100)
3. Liver biopsy showing nonsuppurative destructive cholangitis (used if AMA negative or atypical presentation)
Additional evaluation:
- Ultrasound to rule out biliary obstruction
- FibroScan or elastography for fibrosis staging
- Lipid profile, fat-soluble vitamins, thyroid function
Treatment & Management
Disease-Modifying Therapy
- Ursodeoxycholic acid (UDCA) 13–15 mg/kg/day is first-line; improves survival
- Assess biochemical response (ALP normalization) after 1 year
- Obeticholic acid (OCA) for inadequate responders or UDCA-intolerant patients (avoid in decompensated cirrhosis)
- Fibrates (bezafibrate, fenofibrate) used off-label to enhance response
- Investigational agents: seladelpar, elafibranor, PPAR agonists
Symptom Management
- Pruritus: cholestyramine, rifampin, naltrexone, sertraline
- Fatigue: treat contributing factors (sleep, depression, anemia)
- Sicca: artificial tears/saliva, pilocarpine
- Bone health: DEXA scan, calcium/vitamin D, bisphosphonates if osteopenic
- Lipid management: statins generally safe
Advanced Disease
- Screen for portal hypertension, varices
- Vaccinate against HAV/HBV, screen for HCC in cirrhotic patients
- Early referral for liver transplant when decompensation or MELD ≥ 15
Living with PBC
- Track labs (ALP, bilirubin, AST/ALT), symptoms, medications, side effects
- Maintain balanced diet; moderate exercise to combat fatigue
- Limit alcohol; avoid hepatotoxic drugs
- Manage mental health—fatigue/pruritus can be isolating
Complications
- Cirrhosis, portal hypertension, variceal bleeding
- Hepatocellular carcinoma (especially in men or cirrhotics)
- Malabsorption of fat-soluble vitamins, osteoporosis
- Hyperlipidemia (often with xanthomas)
Research & Future Directions
Research targets bile acid pathways, immune modulation, and antifibrotic strategies.
Experimental & Emerging Treatments
- PPAR Agonists (seladelpar, elafibranor): Show robust ALP reductions and symptomatic improvement.
- FXR Agonists Beyond OCA: Non-steroidal FXR agonists aim to reduce pruritus and improve tolerability.
- Bile Acid Transport Modulators: ASBT inhibitors reduce enterohepatic circulation and pruritus.
- Cell Therapy/Gene Therapy: Investigational therapies aim to restore tolerance and reduce bile duct destruction.
Track PBC with Diagnoza.care
Protect Your Bile Ducts – Log liver labs, imaging, medications, pruritus scores, bone density tests, and transplant evaluations; schedule hepatology visits; capture side effects; and let the AI companion flag trends indicating poor treatment response.
Medical Disclaimer: Informational only. Follow your hepatologist for diagnosis confirmation, treatment escalation, and transplant referral decisions.
Sources: American Association for the Study of Liver Diseases, European Association for the Study of the Liver, British Society of Gastroenterology